Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.80 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.73 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.73 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.70 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.70 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.70 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.67 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.67 |
| ▸ | SRC | P12931 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | DTYMK | P23919 | 2/20 | 0.66 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.65 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.63 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.63 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.63 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5044161 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL29350133 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL3030614 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL29702495 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL14471000 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL18785117 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL78250 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL703733 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL31211719 | 0.99 | POLB (0.81) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL2508784 | 0.99 | POLB (0.81) | POLBP2RY1ENPP1P2RX1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275672-A1 | CHEMICALLY MODIFIED LIGASE COFACTORS, DONORS AND ACCEPTORS | TRILINK BIOTECHNOLOGIES, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275672-A1 | CHEMICALLY MODIFIED LIGASE COFACTORS, DONORS AND ACCEPTORS | TRILINK BIOTECHNOLOGIES, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-9631227-B2 | Chemically modified ligase cofactors, donors and acceptors | TRILINK BIOTECHNOLOGIES, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9631227-B2 | Chemically modified ligase cofactors, donors and acceptors | TRILINK BIOTECHNOLOGIES, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160168636-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-20160168636-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-9163053-B2 | Nucleotide analogs | FLUIDIGM CORPORATION (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163053-B2 | Nucleotide analogs | FLUIDIGM CORPORATION (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140323354-A1 | Chemically Modified Ligase Cofactors, Donors and Acceptors | TRILINK BIOTECHNOLOGIES, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8728725-B2 | Chemically modified ligase cofactors, donors and acceptors | TRILINK BIOTECHNOLOGIES (US) | 2014-05-20 | — | — | US | disclosed |
| US-20110045485-A1 | ANALYTICAL METHOD AND KIT | ENIGMA DIAGNOSTICS LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110045485-A1 | ANALYTICAL METHOD AND KIT | ENIGMA DIAGNOSTICS LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110008788-A1 | CHEMICALLY MODIFIED LIGASE COFACTORS, DONORS AND ACCEPTORS | TriLink Bio Technologies | 2011-01-13 | — | — | US | disclosed |
| US-20110008788-A1 | CHEMICALLY MODIFIED LIGASE COFACTORS, DONORS AND ACCEPTORS | TriLink Bio Technologies | 2011-01-13 | — | — | US | disclosed |
| US-7838236-B2 | Analytical method and kit | ENIGMA DIAGNOSTICS LIMITED (GB) | 2010-11-23 | — | — | US | disclosed |
| US-7838236-B2 | Analytical method and kit | ENIGMA DIAGNOSTICS LIMITED (GB) | 2010-11-23 | — | — | US | disclosed |
| US-20080233588-A1 | Analytical Method and Kit | ENIGMA DIAGNOSTICS LIMITED (GB) | 2008-09-25 | — | — | US | disclosed |
| US-20080233588-A1 | Analytical Method and Kit | ENIGMA DIAGNOSTICS LIMITED (GB) | 2008-09-25 | — | — | US | disclosed |
| US-7371852-B2 | Alkyl-linked nucleotide compositions | SERENEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371852-B2 | Alkyl-linked nucleotide compositions | SERENEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045485-A1 | ANALYTICAL METHOD AND KIT | RNGTT, ADAR, RNASE1 | POLB 95/4885P2RY1 508/4885ENPP1 425/4885 |
| US-20080233588-A1 | Analytical Method and Kit | RNGTT, ADAR, RNASE1 | POLB 69/4885P2RY1 371/4885ENPP1 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.